PMID- 30828914
OWN - NLM
STAT- MEDLINE
DCOM- 20190613
LR  - 20220408
IS  - 1365-3164 (Electronic)
IS  - 0959-4493 (Linking)
VI  - 30
IP  - 3
DP  - 2019 Jun
TI  - Longitudinal evaluation of immunological responses to allergen-specific 
      immunotherapy in horses with IgE associated dermatological disease, a pilot 
      study.
PG  - 255-e78
LID - 10.1111/vde.12732 [doi]
AB  - BACKGROUND: The long-term effects of allergen specific immunotherapy (ASIT) on 
      concentrations of circulating immunoglobulin E (IgE) and immunoglobulin G (IgG) 
      in horses have not been reported. OBJECTIVES: To document changes in clinical 
      severity of horses with atopic dermatitis (AD) and to monitor allergen-specific 
      IgE and IgG concentrations during a two-year course of ASIT. ANIMALS: Nineteen 
      client-owned horses with a conditional diagnosis of AD. METHODS AND MATERIALS: 
      Three ASIT groups were randomly assigned based upon results obtained by either 
      intradermal testing (IDT) for regional allergens (n = 7); enzyme-linked 
      immunosorbent assay (ELISA) for specific IgE (n = 6); or a composite of results 
      from both tests (n = 6). Serum concentrations of IgE and IgG specific for 
      allergens included in ASIT were measured at time zero and at four-month 
      intervals. A visual analog scale (VAS) was used to record severity of clinical 
      signs at times zero, 12 and 24 months. RESULTS: Positive correlations were 
      documented between IgE and both immediate and delayed IDT results (P < 0.00001), 
      and between immediate IDT and IgG results (P = 0.003). Specific IgE in sera 
      decreased significantly (P < 0.05) for allergens that were included in ASIT, 
      whereas IgG increased. Across all horses, the mean VAS score decreased by 1.2 
      units [95% CI: 1.28, 1.14; (P < 0.0001)] during each 12-month period of ASIT 
      therapy. Improvement in clinical signs was noted in 76.5% of the horses following 
      12 months of ASIT and in 82% after 24 months on ASIT. CONCLUSIONS AND CLINICAL 
      IMPORTANCE: In this pilot study, ASIT in horses with AD provided significant 
      clinical benefit associated with a concomitant reduction of allergen-specific IgE 
      and elevation of IgG.
CI  - (c) 2019 ESVD and ACVD.
FAU - Radwanski, Noel E
AU  - Radwanski NE
AUID- ORCID: 0000-0002-1318-7666
AD  - Blue Pearl Veterinary Partners, 3000 Busch Lake Blvd, Tampa, FL, 33614, USA.
FAU - Morris, Daniel O
AU  - Morris DO
AD  - School of Veterinary Medicine, University of Pennsylvania, 3900 Spruce St, 
      Philadelphia, PA, 19104, USA.
FAU - Boston, Raymond C
AU  - Boston RC
AD  - School of Veterinary Medicine, University of Pennsylvania, 3900 Spruce St, 
      Philadelphia, PA, 19104, USA.
FAU - Cerundolo, Rosario
AU  - Cerundolo R
AD  - Dick White Referrals Veterinary Specialist Centre, Six Mile Bottom, 
      Cambridgeshire, CB8 OUH, UK.
FAU - Lee, Kenneth W
AU  - Lee KW
AD  - Greer Laboratories, Inc, 639 Nuway Circle NE, Lenoir, NC, 28645, USA.
LA  - eng
GR  - Greer Laboratories, North Carolina, USA/
PT  - Evaluation Study
PT  - Journal Article
DEP - 20190304
PL  - England
TA  - Vet Dermatol
JT  - Veterinary dermatology
JID - 9426187
RN  - 0 (Allergens)
RN  - 0 (Immunoglobulin G)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens/immunology
MH  - Animals
MH  - Dermatitis, Atopic/therapy/*veterinary
MH  - Desensitization, Immunologic/*veterinary
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Horse Diseases/*immunology/therapy
MH  - Horses/immunology
MH  - Immunoglobulin E/blood/*immunology
MH  - Immunoglobulin G/blood/immunology
MH  - Intradermal Tests/veterinary
MH  - Longitudinal Studies
MH  - Ownership
MH  - Pilot Projects
EDAT- 2019/03/05 06:00
MHDA- 2019/06/14 06:00
CRDT- 2019/03/05 06:00
PHST- 2018/12/21 00:00 [accepted]
PHST- 2019/03/05 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2019/03/05 06:00 [entrez]
AID - 10.1111/vde.12732 [doi]
PST - ppublish
SO  - Vet Dermatol. 2019 Jun;30(3):255-e78. doi: 10.1111/vde.12732. Epub 2019 Mar 4.